| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/02/2003 | US6613783 Non-systemic control of parasites |
| 09/02/2003 | US6613782 For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders |
| 09/02/2003 | US6613781 Potential use in the treatment of a variety of central nervous system disorders such as anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, congnitive disorders, sleep disorders and schizophrenia |
| 09/02/2003 | US6613779 Use of R(+) -α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piper idinemethanol for the treatment of sleep disorders |
| 09/02/2003 | US6613778 Imidazopyridine derivatives as phosphodiesterase VII inhibitors |
| 09/02/2003 | US6613775 Imidazo[1,2-a]pyridine compounds |
| 09/02/2003 | US6613772 Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments |
| 09/02/2003 | US6613770 Quinoline derivatives as NK-2 and NK-3 receptor ligands |
| 09/02/2003 | US6613769 Tryptase inhibitors |
| 09/02/2003 | US6613768 Treatment of female arousal disorder |
| 09/02/2003 | US6613767 Stable aqueous folinate solution |
| 09/02/2003 | US6613766 Compounds such as 3-(5-methylisoxazol-3-yl)-5-(2-pyridyl-methyloxy)-1,2,3a,4,6 -pentaazacyclopenta(a)naphthalene, having high receptivity for the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA); learning enhancement |
| 09/02/2003 | US6613765 Use of NK-1 receptor antagonists for treating major depressive disorders |
| 09/02/2003 | US6613763 Use of molindone to treat oppositional defiant disorder and conduct disorder |
| 09/02/2003 | US6613762 Synergystic mixtures comprising prodrugs, 9,10-dihydrogambogic acid and antibodies, cell growth factors or cytokines, used as anticarcinogenic agents |
| 09/02/2003 | US6613760 Indole derivatives and their use as MCP-1 receptor antagonists |
| 09/02/2003 | US6613758 Method for treating osteoporosis in castrated prostatic cancer patients |
| 09/02/2003 | US6613757 Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy |
| 09/02/2003 | US6613756 Use of tetracycline derivatives in treating multiple sclerosis |
| 09/02/2003 | US6613755 Antimicrobial skin preparations containing organosilane quaternaries |
| 09/02/2003 | US6613754 Plant extracts obtained by solvent extraction and protein removal, used as immunology potentiators and antitumor agents |
| 09/02/2003 | US6613753 Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 09/02/2003 | US6613751 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 09/02/2003 | US6613748 C-glucosyl ether lipids |
| 09/02/2003 | US6613747 6-O-carbamoyl ketolide antibacterials |
| 09/02/2003 | US6613573 Blood coagulation analyzer for determining the efficacy of anti-coagulant therapy by measuring blood clot strength; use in treatment of clotting disorders and in surgical and medical procedures |
| 09/02/2003 | US6613572 Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
| 09/02/2003 | US6613507 Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications |
| 09/02/2003 | US6613367 Complete nutrition of infants products are characterized by the type and amount of protein and carbohydrate and the increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents. These products improve feelings |
| 09/02/2003 | US6613361 Ketoprofen microgranules, method for preparing same and pharmaceutical compositions |
| 09/02/2003 | US6613357 For therapy of respiratory congestion related disorders and allergy related disorders; controlled release |
| 09/02/2003 | US6613356 Medication for weight loss by means of appetite suppression and a method for administering this medication to humans and other mammals. The medication comprises potassium butyrate or closely related chemical compounds, together with chemicals |
| 09/02/2003 | US6613354 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
| 09/02/2003 | US6613350 Electrical apparatus for heating to a desired temperature for improved administration of pharmaceutically active compounds |
| 09/02/2003 | US6613349 Bactericides |
| 09/02/2003 | US6613345 Conjugates of sodium channel blockers and methods of using the same |
| 09/02/2003 | US6613322 Administering enzyme inhibitors |
| 09/02/2003 | US6613321 Strain is unable to express homologous O-polysaccharide due to a 1.2 kb deletion that spans the junction of the rfbA and rfbB genes, and expresses a heterologous O-polysaccharide that is covalently linked to a lipopolysaccharide |
| 09/02/2003 | US6613308 Administering to the respiratory tract a drug at a dose which is at least about two-fold less than the dose required by oral administration. |
| 09/02/2003 | US6613307 Satisfactory dispersions of salmeterol xinafoate in fluorocarbon, hydrogen-containing fluorocarbon or hydrogen-containing chlorofluorocarbon propellants such as 1,1,1,2-tetrafluoroethane |
| 09/02/2003 | CA2216796C Quinazoline derivatives |
| 09/02/2003 | CA2081709C Controlled release pharmaceutical compositions |
| 08/28/2003 | WO2003071281A2 Estrogen receptor interaction with a transcription factor |
| 08/28/2003 | WO2003071267A1 Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| 08/28/2003 | WO2003070971A2 Modulators of paraptosis and related methods |
| 08/28/2003 | WO2003070970A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070968A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070919A1 Antimicrobial composition |
| 08/28/2003 | WO2003070918A2 Rna interference by modified short interfering nucleic acid |
| 08/28/2003 | WO2003070914A2 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070911A2 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r) |
| 08/28/2003 | WO2003070910A2 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070903A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070895A2 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070886A2 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
| 08/28/2003 | WO2003070883A2 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
| 08/28/2003 | WO2003070823A2 Conjugates comprising a biodegradable polymer and uses therefor |
| 08/28/2003 | WO2003070775A1 Novel natural cyclodextrin complexes |
| 08/28/2003 | WO2003070771A1 Rrp sequences and knockout mice and uses thereof |
| 08/28/2003 | WO2003070750A2 Rna interference mediated inhibition of hepatitis c virus |
| 08/28/2003 | WO2003070745A2 Carbonate and carbamate modified forms of glucocorticoids |
| 08/28/2003 | WO2003070744A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/28/2003 | WO2003070739A1 Partial and full agonists of a1 adenosine receptors |
| 08/28/2003 | WO2003070738A2 Topiramate salts and compositions comprising and methods of making and using the same |
| 08/28/2003 | WO2003070733A1 Novel boronate esters |
| 08/28/2003 | WO2003070732A1 Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| 08/28/2003 | WO2003070731A2 Azabicyclic compounds for the treatment of disease |
| 08/28/2003 | WO2003070728A2 Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders |
| 08/28/2003 | WO2003070727A1 Thiazolyl urea compounds for the treatment of cancer |
| 08/28/2003 | WO2003070726A1 Pyranones useful as atm inhibitors |
| 08/28/2003 | WO2003070717A1 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives |
| 08/28/2003 | WO2003070715A1 An antimicrobial agent |
| 08/28/2003 | WO2003070713A1 Substituted aryl alkenoic acid heterocyclic amides possessing pungent taste |
| 08/28/2003 | WO2003070711A1 Oxa- and thiadiazoles and their use as metalloproteinase inhibitors |
| 08/28/2003 | WO2003070707A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| 08/28/2003 | WO2003070706A1 Tricyclic pyrazole derivatives for the treatment of inflammation |
| 08/28/2003 | WO2003070703A2 Hydroxylated indirubin derivatives |
| 08/28/2003 | WO2003070702A1 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
| 08/28/2003 | WO2003070701A2 Syntheses of quinazolinones |
| 08/28/2003 | WO2003070697A1 Method of assaying activity of binding to vitamin d3 receptor using fluorescence polarization |
| 08/28/2003 | WO2003070691A1 N-hydroxycarboxamide derivative |
| 08/28/2003 | WO2003070690A2 Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative |
| 08/28/2003 | WO2003070682A1 NON-COVALENT INHIBITORS OF AmpC ß-LACTAMASE |
| 08/28/2003 | WO2003070675A2 Substituted 10-aryl-11h-benzo[b]fluorenes and 7-aryl-5,6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors |
| 08/28/2003 | WO2003070665A2 Desolvating solvates of atorvastatin hemi-calcium |
| 08/28/2003 | WO2003070315A2 Temperature control system for cutaneous photodynamic therapy |
| 08/28/2003 | WO2003070281A1 Prostaglandin composition for the treatment of erectile dysfunction |
| 08/28/2003 | WO2003070280A2 Absorption enhancing agent |
| 08/28/2003 | WO2003070279A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
| 08/28/2003 | WO2003070278A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
| 08/28/2003 | WO2003070277A1 Antipruritics |
| 08/28/2003 | WO2003070276A1 A preparation and method for weight reduction |
| 08/28/2003 | WO2003070275A1 Use of an inhibitor or antagonist against tissue factor |
| 08/28/2003 | WO2003070273A1 A bioadhesive agent |
| 08/28/2003 | WO2003070270A1 Strategy for retroviral immunotherapy |
| 08/28/2003 | WO2003070269A1 Treatment for diseases of the eye, inner ear and central nervous system |
| 08/28/2003 | WO2003070263A1 Process for producing hydrophobic glycyrrhiza extract with high qualities |
| 08/28/2003 | WO2003070256A1 Hyaluronic acid mediated adenoviral transduction |
| 08/28/2003 | WO2003070255A1 Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12 |
| 08/28/2003 | WO2003070253A1 Estrogenic component for treating decreased libido in women |